S. Korean biotech snags financing with help from U.S. venture group

South Korea-based CrystalGenomics has reeled in $2.6 million in funding from the Korea Seoul Life Science Fund (KSLSF) to advance its R&D programs in pain and infectious diseases, including an NSAID for patients with osteoarthritis, according to a company release. The company noted U.S. venture firm Oxford Bioscience Partners and Hanwha Venture Capital's roles as general partners in its backer KSLSF. The government of South Korea was a major contributor to Boston-based Oxford's sixth fund announced in early 2011. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.